{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:22:29Z","timestamp":1784132549429,"version":"3.55.0"},"reference-count":34,"publisher":"The Endocrine Society","issue":"12","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Amryt Pharmaceuticals"},{"name":"PRECISIONscientia"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>The MPOWERED core trial (NCT02685709) and open-label extension (OLE) phase investigated long-term efficacy and safety of oral octreotide capsules (OOC) in patients with acromegaly. Core trial primary endpoint data demonstrated noninferiority to injectable somatostatin receptor ligands (iSRLs). Core trial completers were invited to participate in the OLE phase.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess long-term efficacy and safety of OOC in patients with acromegaly who previously responded to and tolerated both OOC and injectable octreotide\/lanreotide and completed the core phase.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The unique study design of transitioning between OOC and iSRLs allowed within-patient evaluations. The proportion of biochemical responders (insulin-like growth factor I &amp;lt; 1.3 \u00d7 upper limit of normal) at end of each extension year who entered that year as responders was the main outcome measure.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At year 1 extension end, 52\/58 patients from both the monotherapy and the combination therapy groups were responders (89.7%; 95% CI 78.8-96.1), 36\/41 (87.8%; 95% CI 73.8-95.9) in year 2, and 29\/31 (93.5%; 95% CI 78.6-99.2) in year 3. No new or unexpected safety signals were detected; 1 patient withdrew owing to treatment failure. Patients who transitioned from iSRLs in the core trial to OOC in the OLE phase reported improved treatment convenience\/satisfaction and symptom control.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Patient-reported outcome data support for the first time that transitioning patients randomized to iSRL (who previously responded to both OOC and iSRLs) back to OOC had a significant effect on patients\u2019 symptoms score in a prospective cohort. The MPOWERED OLE showed long-term maintenance of response and sustained safety with OOC.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgad365","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T04:12:14Z","timestamp":1686802334000},"page":"3214-3222","source":"Crossref","is-referenced-by-count":21,"title":["MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9284-6289","authenticated-orcid":false,"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[{"name":"Pituitary Center, Oregon Health & Science University , Portland, OR 97239 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8492-3587","authenticated-orcid":false,"given":"Mark","family":"Molitch","sequence":"additional","affiliation":[{"name":"Endocrinology, Metabolism & Molecular Medicine, Northwestern University Feinberg School of Medicine , Chicago, IL 60611 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dreval","sequence":"additional","affiliation":[{"name":"Department of Clinical Endocrinology of Postgraduate Education Faculty, M.F. Vladimirsky Moscow Regional Research Clinical Institute , Moscow 129110 , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Pokramovich","sequence":"additional","affiliation":[{"name":"Department of Clinical Endocrinology of Postgraduate Education Faculty, M.F. Vladimirsky Moscow Regional Research Clinical Institute , Moscow 129110 , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Bondar","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Novosibirsk State Medical University , Novosibirsk 630090 , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury","family":"Poteshkin","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Pirogov Russian National Research Medical University , Moscow 117997 , Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djuro","family":"Macut","sequence":"additional","affiliation":[{"name":"Department of Endocrine Tumors and Hereditary Cancer Syndromes, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Faculty of Medicine, University of Belgrade , Belgrade 11000 , Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Obermayer-Pietsch","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetology, Medical University Graz , Graz 8036 , Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yossi","family":"Gilgun-Sherki","sequence":"additional","affiliation":[{"name":"Amryt Pharmaceuticals , Dublin D04 W2F1 , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asi","family":"Haviv","sequence":"additional","affiliation":[{"name":"Amryt Pharmaceuticals , Dublin D04 W2F1 , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nienke","family":"Biermasz","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Leiden University Medical Center , Leiden 2333 , Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J","family":"Strasburger","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Charite-Universit\u00e4tsmedizin , Campus Mitte, Berlin 10117 , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"2023111712385990500_dgad365-B1","author":"ClinicalTrials.gov"},{"issue":"2","key":"2023111712385990500_dgad365-B2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","article-title":"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2023111712385990500_dgad365-B3","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11102-020-01038-y","article-title":"An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies","volume":"23","author":"Fleseriu","year":"2020","journal-title":"Pituitary"},{"key":"2023111712385990500_dgad365-B4","doi-asserted-by":"crossref","first-page":"627711","DOI":"10.3389\/fendo.2021.627711","article-title":"Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands","volume":"12","author":"Fleseriu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2023111712385990500_dgad365-B5","author":"Fleseriu"},{"issue":"11","key":"2023111712385990500_dgad365-B6","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"2023111712385990500_dgad365-B7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"2023111712385990500_dgad365-B8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1210\/endrev\/bnac010","article-title":"Clinical biology of the pituitary adenoma","volume":"43","author":"Melmed","year":"2022","journal-title":"Endocr Rev"},{"issue":"5","key":"2023111712385990500_dgad365-B9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nrendo.2011.42","article-title":"Medical therapy in acromegaly","volume":"7","author":"Sherlock","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2023111712385990500_dgad365-B10","doi-asserted-by":"crossref","first-page":"101309","DOI":"10.1016\/j.beem.2019.101309","article-title":"The burden of disease for pituitary patients","volume":"33","author":"Biermasz","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2023111712385990500_dgad365-B11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","article-title":"Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider","volume":"23","author":"Geer","year":"2020","journal-title":"Pituitary"},{"issue":"3","key":"2023111712385990500_dgad365-B12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1136\/jim-2017-000570","article-title":"Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly","volume":"66","author":"Liu","year":"2018","journal-title":"J Investig Med"},{"issue":"3","key":"2023111712385990500_dgad365-B13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023111712385990500_dgad365-B14","first-page":"499","article-title":"Acromegaly: current therapies benefits and burdens","volume":"15","author":"Yedinak","year":"2018","journal-title":"Clin Pract"},{"issue":"1","key":"2023111712385990500_dgad365-B15","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/EJE-17-0041","article-title":"Management of endocrine disease: quality of life tools for the management of pituitary disease","volume":"177","author":"Webb","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2023111712385990500_dgad365-B16","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023111712385990500_dgad365-B17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"2023111712385990500_dgad365-B18","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12020-022-03106-8","article-title":"Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life","volume":"77","author":"Cangiano","year":"2022","journal-title":"Endocrine"},{"issue":"4","key":"2023111712385990500_dgad365-B19","doi-asserted-by":"crossref","first-page":"e60684","DOI":"10.1371\/journal.pone.0060684","article-title":"Patient reported outcomes (PROs) in clinical trials: is \u2018in-trial\u2019 guidance lacking? a systematic review","volume":"8","author":"Kyte","year":"2013","journal-title":"PLoS One"},{"key":"2023111712385990500_dgad365-B20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/PROM.S156279","article-title":"The importance of patient-reported outcomes in clinical trials and strategies for future optimization","volume":"9","author":"Mercieca-Bebber","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"issue":"1","key":"2023111712385990500_dgad365-B21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12955-019-1220-z","article-title":"The impact of patient-reported outcome (PRO) data from clinical trials: a systematic review and critical analysis","volume":"17","author":"Rivera","year":"2019","journal-title":"Health Qual Life Outcomes"},{"issue":"4","key":"2023111712385990500_dgad365-B22","doi-asserted-by":"crossref","first-page":"dgz096","DOI":"10.1210\/clinem\/dgz096","article-title":"A consensus on the diagnosis and treatment of acromegaly comorbidities: an update","volume":"105","author":"Giustina","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023111712385990500_dgad365-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"3","key":"2023111712385990500_dgad365-B24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11102-022-01224-0","article-title":"Quality of life after long-term biochemical control of acromegaly","volume":"25","author":"Kimball","year":"2022","journal-title":"Pituitary"},{"issue":"6","key":"2023111712385990500_dgad365-B25","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1530\/EJE-22-0263","article-title":"Global psychological assessment with evaluation of life and sleep quality, sexual and cognitive function in a large number of patients with acromegaly: a cross-sectional study","volume":"187","author":"Pivonello","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023111712385990500_dgad365-B26","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for acromegaly: long-term outcomes from an extension to the phase III PAOLA study","volume":"182","author":"Colao","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2023111712385990500_dgad365-B27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"2","key":"2023111712385990500_dgad365-B28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The future of somatostatin receptor ligands in acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2023111712385990500_dgad365-B29","doi-asserted-by":"crossref","first-page":"A520","DOI":"10.1210\/jendso\/bvab048.1062","article-title":"Improved acromegaly patient satisfaction with oral octreotide capsules compared with injectable somatostatin receptor ligands in the MPOWERED trial","volume":"5","author":"Gordon","year":"2021","journal-title":"J Endocrin Soc"},{"issue":"6","key":"2023111712385990500_dgad365-B30","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1530\/EJE-22-0220","article-title":"Durable biochemical response and safety with oral octreotide capsules in acromegaly","volume":"187","author":"Samson","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"2023111712385990500_dgad365-B31","doi-asserted-by":"crossref","first-page":"SUN-LB077","DOI":"10.1210\/js.2019-SUN-LB077","article-title":"SUN-LB077 Relationship between responses from acromegaly patients treated with a stable dose of injectable somatostatin analogues in routine clinical practice and their endocrinology health care professional regarding treatment outcomes: preliminary findings","volume":"3","author":"Geer","year":"2019","journal-title":"J Endocrin Soc"},{"issue":"10","key":"2023111712385990500_dgad365-B32","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2023111712385990500_dgad365-B33","doi-asserted-by":"crossref","first-page":"e3644","DOI":"10.1210\/clinem\/dgac385","article-title":"IGF-I variability over repeated measures in patients with acromegaly under long-acting somatostatin receptor ligands","volume":"107","author":"Maione","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023111712385990500_dgad365-B34","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad365\/50836662\/dgad365.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/12\/3214\/53480989\/dgad365.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/12\/3214\/53480989\/dgad365.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T13:38:44Z","timestamp":1700228324000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/12\/3214\/7199096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6,16]]},"published-print":{"date-parts":[[2023,11,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad365","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12]]},"published":{"date-parts":[[2023,6,16]]}}}